James Veal

Dr. James Veal is the CSO and a cofounder of 858 Therapeutics. Jim began his drug discovery career in 1991 at Glaxo Research Institute. While at Glaxo (now GSK), he worked on a range of receptor and enzyme targets, including protein kinases, for the treatment of inflammation and cancer and established himself as an industry leader in the area of applied computational chemistry. In 2003, he joined Serenex Inc. as Senior Director of Structural Chemistry and Informatics, and in 2008, Serenex was acquired by Pfizer for its proteomics platform and drug discovery programs. In 2012, he joined Quanticel Pharmaceuticals as a VP of Drug Discovery and played an integral role in the discovery of multiple development candidates that target cancer stem cells through distinct mechanisms. Following Celgene's acquisition of Quanticel in 2015, Jim was the founding CSO of Jecure Therapeutics, which was acquired by Genentech in 2018 for its NLRP3 discovery program. Jim has contributed to the discovery of several compounds that have advanced to clinical trials including Votrient™ (pazopanib), Tykerb™ (lapatinib), SNX-5422, CC-90010, and CC-90011. He has co-authored numerous scientific publications and is an inventor on multiple issued patents.

Jim received a B.A. in Chemistry from Duke University and a Ph.D. from the Institute of Molecular Biophysics at Florida State University.